c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells by Hsi-Lung Hsieh et al.
RESEARCH Open Access
c-Src-dependent EGF receptor transactivation
contributes to ET-1-induced COX-2 expression in
brain microvascular endothelial cells
Hsi-Lung Hsieh1†, Chih-Chung Lin2†, Hui-Ju Chan3, Caleb M Yang4 and Chuen-Mao Yang3,5*
Abstract
Background: Endothelin-1 (ET-1) is elevated and participates in the regulation of several brain inflammatory
disorders. The deleterious effects of ET-1 on endothelial cells may aggravate brain inflammation mediated
through the upregulation of cyclooxygenase-2 (COX-2) gene expression. However, the signaling mechanisms
underlying ET-1-induced COX-2 expression in brain microvascular endothelial cells remain unclear.
Objective: The goal of this study was to examine whether ET-1-induced COX-2 expression and prostaglandin E2
(PGE2) release were mediated through a c-Src-dependent transactivation of epidermal growth factor receptor
(EGFR) pathway in brain microvascular endothelial cells (bEnd.3 cells).
Methods: The expression of COX-2 induced by ET-1 was evaluated by Western blotting and RT-PCR analysis.
The COX-2 regulatory signaling pathways were investigated by pretreatment with pharmacological inhibitors,
short hairpin RNA (shRNA) or small interfering RNA (siRNA) transfection, chromatin immunoprecipitation (ChIP),
and promoter activity reporter assays. Finally, we determined the PGE2 level as a marker of functional activity of
COX-2 expression.
Results: First, the data showed that ET-1-induced COX-2 expression was mediated through a c-Src-dependent
transactivation of EGFR/PI3K/Akt cascade. Next, we demonstrated that ET-1 stimulated activation
(phosphorylation) of c-Src/EGFR/Akt/MAPKs (ERK1/2, p38 MAPK, and JNK1/2) and then activated the c-Jun
/activator protein 1 (AP-1) via Gq/i protein-coupled ETB receptors. The activated c-Jun/AP-1 bound to its
corresponding binding sites within COX-2 promoter, thereby turning on COX-2 gene transcription. Ultimately,
upregulation of COX-2 by ET-1 promoted PGE2 biosynthesis and release in bEnd.3 cells.
Conclusions: These results demonstrate that in bEnd.3 cells, c-Src-dependent transactivation of EGFR/PI3K/Akt
and MAPKs linking to c-Jun/AP-1 cascade is essential for ET-1-induced COX-2 upregulation. Understanding the
mechanisms of COX-2 expression and PGE2 release regulated by ET-1/ETB system on brain microvascular
endothelial cells may provide rational therapeutic interventions for brain injury and inflammatory diseases.
Background
Cyclooxygenase (COX) is a rate-limiting key enzyme in
the synthesis of prostaglandins (PGs) and thromboxane.
In this process, phospholipase A2 catalyzes the release of
arachidonic acid (AA) from membrane phospholipids,
while COX catalyzes the conversion of AA into PGH2,
which is the common precursor of all prostanoids [1,2].
Two COX isoforms have been demonstrated: COX-1,
which is constitutively expressed in most tissues, regu-
lates normal physiological responses and controls renal
and vascular homeostasis; COX-2, another COX iso-
form, is not detectable in most normal tissues or resting
cells, but its expression can be induced by various stim-
uli, including cytokines, endotoxin, and growth factors
to produce proinflammatory PGs during inflammatory
responses in several cell types including vascular endo-
thelial and smooth muscle cells [3,4]. Previous studies
have shown that COX-2 immunoreactivity is detected in
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various inflammatory tissues, including synovial macro-
phage and vascular cells of patients with arthritis and
atherosclerosis, respectively. Several lines of evidence
have further confirmed COX-2 as a major therapeutic
target for the treatment of inflammatory disorders such
as arthritis [1]. Moreover, homozygous deletion of the
COX-2 gene in mice leads to a striking reduction of
endotoxin-induced inflammation [5]. Therefore, COX-2
may play an important role in the development of vari-
ous inflammatory responses such as vascular inflamma-
tion (i.e., atherosclerosis and hypertension). In brain,
upregulation of COX-2 leads to increased production of
PGs, which are potent inflammatory mediators asso-
ciated with neurodegenerative disorders [6]. Thus, COX-
2 and its metabolites PGs may act as a major patho-
logical factor in brain inflammatory diseases.
The endothelium plays an important role in the regu-
lation of vascular function by producing a large number
of biologically active substances that participate in the
regulation of vascular functions. In brain, cerebral capil-
lary and microvascular endothelial cells play an active
role in maintaining cerebral blood flow, microvascular
tone, and blood–brain barrier (BBB) functions [7]. Dys-
function of the vascular endothelium is an early finding
in the development of various vascular diseases and is
closely related to clinical events in patients with athero-
sclerosis and hypertension [8,9]. Endothelial cells are
known to produce vasoactive mediators such as
endothelin (ET) to maintain hemodynamic responses.
Among the ET family, the bioactivity of ET-1 is
mediated through potent vasoconstrictor and proinflam-
matory action, and has been implicated in the pathogen-
esis of hypertension and vascular diseases [9-11]. Two
types of ET receptors, ET type A (ETA) and type B
(ETB), are responsible for ET-1-triggered biological
effects, which are mediated via G protein-dependent
regulation [12]. In the central nervous system (CNS),
ET-1 also plays a substantial role in the normal develop-
ment or in CNS diseases. Both endothelial cells [13] and
astrocytes [14] are potential sources of ET-1 release in
response to hypoxic/ischemic injury of the brain. The
ETB receptors are located on both endothelial and vas-
cular smooth muscle cells, and modulate post-injury
responses of these cells in the CNS [11]. There has been
an increasing interest in the regulatory role of endothe-
lial cells in neurovascular coupling, which matches an
adequate supply of cerebral blood flow with the local
metabolic demands that are imposed by neural activity
[15]. As a fundamental component of the neurovascular
unit, endothelium dysfunction has been implicated in
neurodegenerative diseases [15,16]. Circumstantial evi-
dence has further demonstrated that overexpression of
ET-1 on endothelial cells has deleterious effects on is-
chemic brain [7]. Endothelial ET-1 can induce cytokine
or chemokine (e.g., interleukin-1 or interleukin-8) pro-
duction and secretion by non-neuronal cells, including
astrocytes and endothelial cells, which directly contrib-
ute to BBB breakdown during CNS inflammation [17].
These findings imply the involvement of ET-1 in neu-
roinflammation in the CNS. However, the detailed
mechanisms responsible for ET-1 action remain unclear.
ET-1 activates multiple signaling pathways and regu-
lates diverse cellular functions via ET receptors (ETA or
ETB), which couple to various G proteins such as Gq and
Gi [12,18-20]. The principal mechanism underlying acti-
vation by ET-1 is mediated through ETB receptors coup-
ling Gq proteins, resulting in activation of phospholipase
C (PLC)-β, phosphoinositide (PI) hydrolysis, and forma-
tion of inositol trisphosphate (IP3) and diacylglycerol,
leading to Ca2+ increase and protein kinase C (PKC) acti-
vation [21]. Activation of ETB receptor has been also
shown to inhibit adenylyl cyclase via coupling to Gi pro-
teins [22]. Several lines of evidence demonstrate that
mitogen-activated protein kinases (MAPKs) could be
activated by the activation of Gq and Gi protein-coupled
receptors via different signal pathways [23]. MAPKs acti-
vation by ET-1 has been shown to modulate various cel-
lular responses, including cellular hypertrophy, growth,
proliferation, and cell survival in various cell types
[19,24]. Induction of COX-2 expression requires activa-
tion of MAPK and stimulation of particular transcription
factors in various cell types [20,25,26]. Moreover, it has
been shown that signaling through MAPKs, extracellular
signal-regulated protein kinase 1/2 (ERK1/2) especially,
in response to GPCR agonists can be mediated through
transactivation of the epidermal growth factor receptor
(EGFR) [27]. The transactivation of EGFR by GPCRs
mediated by activation of non-receptor tyrosine kinases
such as the Src family or release of heparin-binding EGF-
like growth factor (HB-EGF) has been demonstrated in
various cell types [28]. ET-1 has also been shown to share
this transactivation of EGFR in ovarian cancer cells or
VSMCs, leading to MAPK activation and then regulating
cell proliferation or COX-2 expression, respectively
[29,30]. Our previous report demonstrated that bradyki-
nin stimulates ERK1/2 activation and cell proliferation
via Src family kinases and EGFR transactivation in
VSMCs [31]. Additionally, ET-1 can stimulate transacti-
vation of EGFR via ETA receptors in rat cardiac fibro-
blasts [32]. Several previous reports have also
demonstrated that GPCR agonists (e.g., sphingosine 1-
phosphate and thrombin) stimulate ERK1/2 phosphoryl-
ation and AP-1 activation associated with COX-2 expres-
sion in rat VSMCs [4,31]. However, several reports have
demonstrated that proinflammatory stimuli, which play a
critical role in inflammation, rapidly upregulate AP-1-
dependent genes such as COX-2 [33-35]. In brain micro-
vascular endothelial cells, the mechanisms underlying
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ET-1-induced COX-2 expression and PGE2 production
are not completely defined, the c-Src-dependent transac-
tivation of EGFR cascade especially.
In this study, we investigated the molecular mechan-
isms underlying ET-1-induced COX-2 expression in
mouse brain microvascular endothelial (bEnd.3) cells.
These findings suggested that ET-1 induces COX-2 ex-
pression at the transcriptional and translational levels,
which is mediated through the ETB receptor (coupling
to Gi and Gq)-mediated c-Src-dependent transactivation
of EGFR and activation of PI3K/Akt, ERK1/2, p38
MAPK, JNK1/2, and c-Jun/AP-1 pathways, leading to
PGE2 biosynthesis in mouse bEnd.3 cells. These results
provide new insights into the mechanisms of ET-1 ac-




Dulbecco’s modified Eagle’s medium (DMEM)/F-12
medium, fetal bovine serum (FBS), and TRIzol were
from Invitrogen (Carlsbad, CA). The Hybond C mem-
brane and enhanced chemiluminescence (ECL) Western
blot detection system were from GE Healthcare Bios-
ciences (Buckinghamshire, UK). Anti-COX-2 monoclo-
nal antibody was from BD Transduction Laboratories
(San Diego, CA). Phospho-c-Src (#2120), Phospho-EGFR
(#2231), Phospho-Akt (#9271), Phospho-ERK1/2 (#9101),
Phospho-p38 (#9211), Phospho-JNK1/2 (#9255), and
Phospho-c-Jun (#2361) antibodies were from Cell Signal-
ing (Danver, MA). c-Src (sc-8056), EGFR (sc-03), p85 (sc-
423), Akt (sc-8312), and c-Jun (sc-1694) antibodies were
from Santa Cruz (Santa Cruz, CA). Anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, cat. no. 4699–
9555) antibody was from Biogenesis (Boumemouth, UK).
Genistein, PP1, AG1478, LY294002, SH-5, BQ-123,
BQ-788, GP antagonist-2, GP antagonist-2A, U0126,
SB202190, SP600125, and tanshinone IIA were from
Biomol (Plymouth Meeting, PA). Bicinchoninic acid
(BCA) protein assay reagent was from Pierce (Rock-
ford, IL). Enzymes, ET-1, and other chemicals were
from Sigma (St. Louis, MO).
Mouse brain microvascular endothelial cell culture
Mouse brain microvascular endothelial cells (bEnd.3)
were purchased from Bioresource Collection and Re-
search Centre (BCRC, Hsinchu, Taiwan) and were grown
in DMEM/F-12 containing 10% FBS and antibiotics (100
U/ml penicillin G, 100 μg/ml streptomycin, and 250 ng/
ml fungizone) at 37 °C in a humidified 5% CO2 atmos-
phere. When the cultures had grown to confluence, cells
were released with 0.05% (w/v) trypsin/0.53 mM EDTA
for 5 min at 37 °C. The cell suspension was diluted with
DMEM/F-12 containing 10% FBS to a concentration of
2 × 105 cells/ml. The cell suspension was plated onto 6-
well culture plates (2 ml/well) or 10-cm culture dishes
(10 ml/dish) for the measurement of protein or RNA ex-
pression, respectively. Culture medium was changed
after 24 h and then every 3 days. Experiments were per-
formed with cells from passages 5 to 13.
Preparation of cell extracts and Western blot analysis
Growth-arrested cells were incubated with ET-1 at 37 °C
for various time intervals. The cells were washed with
ice-cold phosphate-buffered saline (PBS), scraped, and
collected by centrifugation at 45,000 × g for 1 h at 4 °C
to yield the whole cell extract, as described previously
[4]. Samples were denatured, subjected to SDS-PAGE
using a 10% (w/v) running gel, and transferred to nitro-
cellulose membrane. Membranes were incubated over-
night using an anti-COX-2, Phospho-c-Src, Phospho-
EGFR, Phospho-Akt, Phospho-ERK1/2, Phospho-p38,
Phospho-JNK1/2, and Phospho-c-Jun, c-Src, EGFR, p85,
Akt, c-Jun, or GAPDH antibody (1:1,000 dilution).
Membranes were washed with TTBS four times for 5
min each, incubated with a 1:2,000 dilution of anti-
rabbit horseradish peroxidase antibody for 1 h. The
immunoreactive bands were detected by ECL reagents.
Total RNA extraction and gene expression
For reverse transcription PCR (RT-PCR) analysis, total
RNA was extracted from mouse brain endothelial cells
stimulated by ET-1, as previously described [4]. The
cDNA obtained from 0.5 μg total RNA was used as a
template for PCR amplification. Oligonucleotide pri-
mers were designed based on Genbank entries for
mouse COX-2 and β-actin. The following primers were





sense). PCR mixes contained 10 μl of 5× PCR buffer,
1.25 mM of each dNTP, 100 pmol of each forward
and reverse primer, and 2.5 units of Taq polymerase
(Takara, Shiga, Japan). The final reaction volume was
50 μl. Amplification was performed in 25 cycles at 94
°C, 20 s; 60 °C, 40 s; 72 °C, 40 s [36]. After the last
cycle, all samples were incubated for an additional 10
min at 72 °C. PCR fragments were analyzed on 2%
agarose 1× TAE gel containing ethidium bromide, and
their size was compared to a molecular weight marker.
Amplification of β-actin, a relatively invariant internal
reference RNA, was performed in parallel, and cDNA
amounts were standardized to equivalent β-actin
mRNA levels. These primer sets specifically recognized
only the genes of interest as indicated by amplification
of a single band of the expected size (500 bp for
Hsieh et al. Journal of Neuroinflammation 2012, 9:152 Page 3 of 15
http://www.jneuroinflammation.com/content/9/1/152
COX-2 and 514 bp for β-actin) and direct sequence
analysis of the PCR products.
Plasmid construction, transient transfection, and
luciferase assays
The mouse COX-2 promoter was constructed as
described previously [37] with some modifications. The
upstream region (−907 to +70) of the mouse COX-2
promoter was cloned to the pGL3-basic vector contain-
ing the luciferase reporter system. Introduction of a
double-point mutation into the AP-1-binding site
(ACAGTCA to ACAACCA) to generate pGL-COX2-
mAP1 was performed using the following (forward) pri-
mer: 5′-GGTACCGACGTACAGACCAGACACGG-3′.
The underlined nucleotides indicate the positions of
substituted bases. The mutant construct was cloned into
the pGL3-basic vector containing the luciferase reporter
system. All plasmids were prepared by using QIAGEN
plasmid DNA preparation kits. The shRNA for c-Src,
EGFR, p85, and Akt was provided by Dr. C.P. Tseng
(Chang Gung University). The siRNAs for c-Jun and
scrambled control were from Dharmacon Research Inc.
(Lafayette, CO, USA), and AP-1-promoter or COX-2
promoter reporter construct was transfected into cells
using the Lipofetamine-2000 transfection reagent
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). The transfection efficiency (~60%) was
determined by transfection with enhanced EGFP. To as-
sess promoter activity, cells were collected and disrupted
by sonication in lysis buffer (25 mM Tris-phosphate, pH
7.8, 2 mM EDTA, 1% Triton X-100, and 10% glycerol).
After centrifugation, aliquots of the supernatants were
tested for luciferase activity using a luciferase assay sys-
tem. Firefly luciferase activities were standardized to β-
galactosidase activity.
Chromatin immunoprecipitation (ChIP) assay
The assay was performed as described previously [38] with
modifications. In brief, bEnd.3 cells were cross-linked with
1% formaldehyde for 10 min at 37 °C and washed three
times with ice-cold PBS containing 1 mM phenylmethyl-
sulfonyl fluoride (PMSF) and 1% aprotinin. Soluble chro-
matin was prepared using a ChIP assay kit (Upstate)
according to the manufacturer’s recommendations, and
immunoprecipitated without (control) or with anti-c-Jun
antibody and normal goat immunoglobulin G (IgG). Fol-
lowing washes and elution, precipitates were heated over-
night at 65 °C to reverse cross-linking of DNA and protein.
DNA fragments were purified by phenol-chloroform ex-
traction and ethanol precipitation. The purified DNA was
subjected to PCR amplification using the primers specific
for the region (−371 to +70) containing AP-1-binding do-
main present in the COX-2 promoter, sense primer: 5′-
GGGGGAGGGAAGCTGTGACACTCTTGAGCTTT-3′
antisense primer: 5′-GACAGTGCTGAGATTCTTCGT-
GAGCAGAGTCC-3′. PCR fragments were analyzed on
2% agarose 1× TAE gel containing ethidium bromide, and
the size (440 bp) was compared to a molecular weight
marker.
Measurement of PGE2 release
The cells were seeded in 12-well plates and grown to
confluence. Cells were shifted to serum-free DMEM/F-
12 medium for 24 h, and then treated with ET-1 for
various time intervals. The culture supernatants were
collected to measure PGE2 levels using an EIA kit as
specified by the manufacturer (Cayman Chemical).
Analysis of data
All data were estimated using GraphPad Prism Program
(GraphPad, San Diego, CA). Quantitative data were ana-
lyzed by one-way ANOVA followed by Tukey’s honestly
significant difference tests between individual groups.
Data were expressed as mean ± SEM. A value of P< 0.05
was considered significant.
Results
The c-Src tyrosine kinase mediates ET-1-induced COX-2
expression in bEnd.3 cells
It has been well established that cytoplasmic tyrosine
kinases of the c-Src family are involved in signaling
events evoked by G protein-coupled receptors (GPCRs),
which modulate many cellular functions. To determine
whether c-Src is involved in ET-1-induced COX-2 ex-
pression in bEnd.3 cells, a pan-protein tyrosine kinases
inhibitor genistein and a selective pharmacological in-
hibitor of c-Src were used. As shown in Figure 1A-D,
pretreatment with genistein (Gen) or PP1 for 1 h prior
to exposure to ET-1 for 6 or 1 h concentration-
dependently blocked ET-1-induced COX-2 protein or
mRNA expression. To further demonstrate whether ET-
1 stimulates phosphorylation of c-Src, which is involved
in these responses, as shown in Figure 1E, ET-1 stimu-
lated a time-dependent phosphorylation of c-Src with a
maximal response within 30 s in bEnd.3 cells. Pretreat-
ment with PP1 (100 nM) significantly attenuated ET-1-
stimulated phosphorylation of c-Src during the period of
observation. To further ensure the involvement of c-Src
in ET-1-induced COX-2 expression, transfection of cells
with c-Src shRNA downregulated the total c-Src protein
and attenuated ET-1-induced COX-2 expression
(Figure 1F). The results demonstrated that ET-1-induced
COX-2 expression is mediated through a c-Src-
dependent pathway in bEnd.3 cells.
ET-1 induces COX-2 expression via transactivation of
EGFR
Cross-talk between GPCRs and RTKs has been shown
to regulate the expression of several target proteins in
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various cell types. It has been reported that transactiva-
tion of RTKs, EGFR especially, mediates signalings acti-
vated by GPCR ligands, such as ET-1, lysophosphatidic
acid, and bradykinin [27,39]. To examine whether RTK
transactivation is required for ET-1-induced COX-2 ex-
pression, as shown in Figure 2A and B, pretreatment
with a selective EGFR inhibitor AG1478 blocked ET-1-
induced COX-2 protein and mRNA expression in a
concentration-dependent manner. Furthermore, to dem-
onstrate whether ET-1 stimulates EGFR phosphoryl-
ation, bEnd.3 cells were stimulated with ET-1 for the
indicated time intervals. The data showed that ET-1 sti-
mulated EGFR phosphorylation in a time-dependent
manner with a maximal response within 30–60 s
(Figure 2C). Pretreatment with AG1478 (10 μM) inhibited
ET-1-stimulated EGFR phosphorylation during the period
of observation. To confirm that EGFR is essential for ET-
1-induced COX-2 expression, as shown in Figure 2D,
transfection with EGFR shRNA downregulated the total
EGFR protein and attenuated ET-1-induced COX-2 ex-
pression. The results suggested that transactivation of
RTK (EGFR) is involved in ET-1-induced COX-2 expres-
sion in bEnd.3 cells.
Involvement of PI3K/Akt cascade in ET-1-induced COX-2
expression
Akt has been shown to be a downstream component of
the EGFR pathway. Thus, we examined whether the
Figure 1 ET-1 induces COX-2 expression via c-Src tyrosine kinase in bEnd.3 cells. (A,B) Involvement of protein tyrosine kinases in ET-1-
induced COX-2 expression; cells were pretreated with various concentrations of genistein (0.1, 1, or 10 nM) for 1 h and incubated with 10 nM ET-
1 for 6 h (A) or 1 h (B). (C,D) Involvement of c-Src tyrosine kinase in ET-1-induced COX-2 expression; cells were pretreated with various
concentrations of PP1 (1, 10, or 100 nM) for 1 h and incubated with 10 nM ET-1 for 6 h (C) or 1 h (D). (E) Time dependence of ET-1-induced c-Src
phosphorylation; cells were treated with 10 nM ET-1 for the indicated time intervals in the presence or absence of PP1 (100 nM). The
phosphorylation of c-Src was analyzed by Western blot using an anti-phospho-c-Src antibody. (F) Cells were transfected with shRNA of c-Src (sh-
Src) for 24 h (Topo: as a control) and treated with 10 nM ET-1 for 6 h. The COX-2 protein (A,C,F) and mRNA (B,D) were analyzed by Western
blotting and RT-PCR, respectively. Data are expressed as mean± SEM of three individual experiments (n= 3). *P< 0.05, #P< 0.01 as compared with
cells stimulated by ET-1 alone.
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PI3K/Akt cascade is involved in ET-1-induced
responses; the inhibitors of PI3K (LY294002) and Akt
(SH-5) [40] were used. As shown in Figure 3A and B,
pretreatment of cells with LY294002 or SH-5
concentration-dependently attenuated COX-2 protein
and mRNA induction by ET-1, implying the involve-
ment of the PI3K/Akt cascade in ET-1-induced COX-2
expression. Next, to ensure whether ET-1 stimulates
PI3K/Akt cascade activation, cells were stimulated with
ET-1 for the indicated time intervals, and the activation
of Akt was determined by Western blotting using an
anti-phospho-Akt antibody. The data showed that ET-1
stimulated Akt phosphorylation in a time-dependent
manner with a maximal response within 5–10 min
(Figure 3C). Pretreatment with an Akt inhibitor SH-5
(10 nM) markedly attenuated ET-1-stimulated Akt
phosphorylation during the period of observation. To
further confirm the role of the PI3K/Akt cascade in
ET-1-induced COX-2 expression, as shown in
Figure 3D, transfection with p85 or Akt shRNA blocked
the total level of p85 or Akt protein and attenuated ET-
1-induced COX-2 expression. The results indicated that
the PI3K/Akt cascade plays a critical role in ET-1-
induced COX-2 expression in bEnd.3 cells.
The c-Jun/AP-1 is required for ET-1-induced COX-2
expression and PGE2 release
It is well known that the COX-2 promoter consists of
AP-1 binding sites [33]. Therefore, we determined
whether the transcription factor AP-1 is involved in ET-
1-induced COX-2 expression in bEnd.3 cells; an AP-1
inhibitor tanshinone IIA (TSIIA) was used. The data
showed that pretreatment with TSIIA significantly inhib-
ited ET-1-induced COX-2 protein and mRNA expres-
sion in a concentration-dependent manner (Figure 4A
and B). AP-1 consists of homodimers of the Jun family
or heterodimers of Jun and Fos family proteins [41].
Here we further investigated whether ET-1 stimulates
AP-1 activation through regulating phosphorylation of
c-Jun/AP-1; as shown in Figure 4C, ET-1 stimulated a
time-dependent phosphorylation of c-Jun with a max-
imal response within 15–30 min in bEnd.3 cells, which
was attenuated by pretreatment with TSIIA during
the period of observation. Subsequently, to further
Figure 2 Transactivation of EGFR is involved in ET-1-induced COX-2 expression. (A,B) Cells were pretreated with various concentrations of
AG1478 (0.1, 1, or 10 μM) for 1 h and incubated with 10 nM ET-1 for 6 h (A) or 1 h (B). (C) Time dependence of ET-1-induced EGFR
phosphorylation; cells were treated with 10 nM ET-1 for the indicated time intervals in the presence or absence of AG1478 (10 μM). The
phosphorylation of EGFR was analyzed by Western blot using an anti-phospho-EGFR antibody. (D) Cells were transfected with shRNA of EGFR (sh-
EGFR) for 24 h (Topo: as a control) and incubated with 10 nM ET-1 for 6 h. The COX-2 protein (A,D) and mRNA (B) were analyzed by Western
blotting and RT-PCR, respectively. Data are expressed as mean± SEM of three individual experiments (n= 3). *P< 0.05, #P< 0.01 as compared with
cells stimulated by ET-1 alone.
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demonstrate that c-Jun is involved in the response, in-
deed, a siRNA of c-Jun was used. The data showed that
transfection of cells with c-Jun siRNA downregulated
the c-Jun protein expression and markedly attenuated
ET-1-induced COX-2 expression (Figure 4D). We fur-
ther determined whether c-Jun/AP-1 is also involved in
ET-1-induced PGE2 release; as shown in Figure 4E, pre-
treatment with TSIIA or transfection with c-Jun siRNA
significantly attenuated PGE2 release induced by ET-1,
suggesting that c-Jun/AP-1 participates in ET-1-induced
COX-2 expression and PGE2 release in bEnd.3 cells.
ET-1 stimulates c-Src-dependent transactivation of EGFR/
PI3K/Akt leading to MAPKs and c-Jun phosphorylation
We have demonstrated that ET-1-induced COX-2 ex-
pression is mediated through activation of c-Src, EGFR,
PI3K/Akt, or c-Jun/AP-1. Thus, we made an attempt to
sequentially differentiate the signaling pathway of these
molecules. First, cells were pretreated with antagonists
of ETB receptor (BQ788) or G proteins (e.g., GPAnt2 for
Gi or Gs protein and GPAnt2A for Gq protein) [42] for 1
h prior exposure to ET-1 for the indicated time intervals.
As shown in Figure 5A, ET-1-stimulated c-Src phos-
phorylation was significantly attenuated by pretreatment
with BQ788 (1 μM), GPAnt2 (1 μM), and GPAnt2A
(1 μM), but not AG1478 and LY294002, suggesting that
phosphorylation of c-Src by ET-1 was mediated through
a Gi and Gq protein-coupled ETB receptor. Next,
pretreatment with BQ788, GPAnt2, GPAnt2A, or PP1
(100 nM) all markedly inhibited ET-1-stimulated EGFR
phosphorylation at tyrosine 845 (Tyr845) residue, which
was one of the phosphorylation sites by c-Src kinases
during the observation period (Figure 5B). These results
suggested that ET-1-transactivated EGFR may be
Figure 3 ET-1-induced COX-2 expression is mediated through PI3K/Akt cascade. (A,B) Cells were pretreated with various concentrations of
LY294002 (3, 30, or 300 nM) or SH-5 (1, 10, or 100 nM) for 1 h, and incubated with 10 nM ET-1 for 6 h (A) or 1 h (B). (C) Time dependence of ET-
1-induced Akt phosphorylation; cells were treated with 10 nM ET-1 for the indicated time intervals in the presence or absence of SH-5 (10 nM).
The phosphorylation of Akt was analyzed by Western blot using an anti-phospho-Akt antibody. (D) Cells were transfected with p85 (sh-p85) or
Akt (sh-Akt) shRNA for 24 h (Topo: as a control) and incubated with 10 nM ET-1 for 6 h. The COX-2 protein (A,D) and mRNA (B) were analyzed by
Western blotting and RT-PCR, respectively. Data are expressed as mean± SEM of three individual experiments (n= 3). *P< 0.05, #P< 0.01 as
compared with cells stimulated by ET-1 alone.
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mediated through a Gi and Gq protein-coupled ETB re-
ceptor linking to c-Src-dependent cascade. Furthermore,
we demonstrated whether the EGFR downstream signal-
ing molecule Akt could be activated by the same path-
way; cells were pretreated with BQ788, GPAnt2,
GPAnt2A, PP1, AG1478 (1 μM), or LY294002 (300 nM)
for 1 h and then stimulated with ET-1 for the indicated
time intervals. As shown in Figure 5C, ET-1-stimulated
Akt phosphorylation was attenuated by pretreatment
with these pharmacological inhibitors, suggesting that
phosphorylation of Akt by ET-1 was mediated via c-Src-
dependent transactivation of EGFR. Furthermore, our
previous reports have demonstrated that thrombin or
BK stimulates activation of MAPKs via a c-Src-
dependent EGFR transactivation in vascular smooth
muscle cells [4,31]. Thus, to further determine whether
ET-1 stimulates activation of MAPKs via c-Src-
dependent EGFR transactivation, cells were pretreated
with PP1, AG1478, or LY294002 before exposure to ET-
1 for the indicated time intervals. As expected, we found
that ET-1 stimulated phosphorylation of MAPKs,
including ERK1/2, p38 MAPK, and JNK1/2, in a time-
dependent manner (Figure 5D). Moreover, pretreatment
with PP1, AG1478, or LY294002 significantly attenuated
ET-1-stimulated phosphorylation of ERK1/2, p38
MAPK, and JNK1/2 (Figure 5D), suggesting that ET-1
stimulates MAPKs phosphorylation via a c-Src-
dependent EGFR/PI3K/Akt cascade. Pretreatment with
the inhibitor of ERK (U0126, 1 μM), p38 MAPK
(SB202190, 300 nM), or JNK (SP600125, 300 nM) mark-
edly attenuated ET-1-induced COX-2 expression
(Figure 5D, lower panel), suggesting that ET-1-induced
COX-2 expression is mediated through these MAPKs.
We further demonstrated whether activation of c-Jun/
AP-1 by ET-1 was also mediated through c-Src-
dependent transactivation of EGFR/PI3K/Akt and
MAPKs in b.End.3 cells. As shown in Figure 5E, pre-
treatment with these inhibitors as described above
markedly attenuated ET-1-stimulated phosphorylation of
c-Jun during the period of observation, suggesting that
ET-1 stimulated c-Jun phosphorylation via the same
pathway. These results indicated that ET-1-induced
Figure 4 AP-1/c-Jun is essential for ET-1-induced COX-2 expression. (A,B) Cells were pretreated with various concentrations of tanshinone
IIA (TSIIA, 1, 10, or 100 nM) for 1 h and incubated with 10 nM ET-1 for 6 h (A) or 1 h (B). (C) Time dependence of ET-1-induced c-Jun/AP-1
phosphorylation; cells were treated with 10 nM ET-1 for the indicated time intervals in the presence or absence of TSIIA (100 nM). The
phosphorylation of c-Jun/AP-1 was analyzed by Western blot using an anti-phospho-c-Jun antibody. (D) Cells were transfected with siRNA of c-
Jun (si-c-Jun) or scrambled (scrm; as a control) for 24 h and incubated with 10 nM ET-1 for 6 h. The COX-2 protein (A,D) and mRNA (B) were
analyzed by Western blotting and RT-PCR, respectively. (E) Involvement of c-Jun/AP-1 in PGE2 release induced by ET-1; cells were pretreated with
TSIIA (100 nM) or transfected with c-Jun siRNA (si-c-Jun) and then incubated with ET-1 (10 nM) for 6 h. The conditioned media were collected to
assay PGE2 level by EIA kit. Data are expressed as mean± SEM of three individual experiments (n= 3).
#P< 0.01 as compared with cells stimulated
by ET-1 alone.
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Figure 5 (See legend on next page.)
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MAPKs-dependent c-Jun phosphorylation was mediated
through c-Src-dependent transactivation of EGFR/PI3K/
Akt in bEnd.3 cells.
ET-1 stimulates AP-1 activation and recruitment of AP-1
to COX-2 gene promoter via c-Src-dependent EGFR/PI3K/
Akt/MAPKs pathway
To investigate whether ET-1-stimulated AP-1 transcrip-
tion activity is also mediated through this c-Src-
dependent pathway, the AP-1 promoter reporter con-
struct was used. As shown in Figure 6A, ET-1 (10 nM)
stimulated an AP-1-luciferase activity increase in a time-
dependent manner with a maximal response within 90
min, which was attenuated by pretreatment with TSIIA
(100 nM) [43]. Furthermore, pretreatment with PP1,
AG1478, LY294002, SH-5, U0126, SB202190, or
SP600125 also attenuated ET-1-stimulated AP-1 tran-
scriptional activity (Figure 6B). It has been shown that
the COX-2 promoter region contains AP-1 binding sites.
Hence, we used a ChIP-PCR assay to determine whether
ET-1-stimulated recruitment of c-Jun/AP-1 to the COX-
2 promoter is involved in COX-2 gene expression. We
designed a pair of primers for the COX-2 promoter
(−371 to +70) region, containing an AP-1 binding site.
Chromatin was immunoprecipitated using an anti-c-Jun
antibody, and the COX-2 promoter region was amplified
by PCR. As shown in Figure 6C (upper part), ET-1 sti-
mulated in vivo binding of c-Jun to the COX-2 promoter
in a time-dependent manner with a maximal response
within 90 min, which was attenuated by pretreatment
with TSIIA, U0126, SB202190, SP600125, or BQ788
(Figure 6C, lower part).
We next examined whether ET-1-induced COX-2 pro-
moter activity is also regulated by these signaling path-
ways. ET-1-stimulated increase in COX-2 promoter
activity was attenuated by pretreatment with PP1,
AG1478, LY294002, SH-5, U0126, SB202190, SP600125,
or TSIIA (Figure 6D), suggesting that ET-1-induced
COX-2 promoter activity is mediated through c-Src-
dependent EGFR/PI3K/Akt/MAPKs and c-Jun/AP-1 in
bEnd.3 cells. To further ensure that AP-1 is involved in
ET-1-induced COX-2 promoter activity via binding to
the AP-1 binding element on the COX-2 promoter re-
gion, the wild-type COX-2 promoter mutated by single-
point mutation of the AP-1 binding site (mu-AP-1) was
constructed (as illustrated in Figure 6E, upper part). ET-
1-stimulated COX-2 promoter activity was significantly
blocked in cells transfected with an mt-AP1-COX-2 re-
porter construct (Figure 6E, lower part). These results
confirmed that ET-1-induced COX-2 promoter activity
is mediated through binding of AP-1 (c-Jun) to the AP-1
element of the COX-2 promoter region.
ET-1-induced PGE2 release is mediated through c-Src-
dependent transactivation of EGFR
Ultimately, to demonstrate the functional activity of
upregulated COX-2 by ET-1 on bEnd.3 cells, we evalu-
ated the PGE2 release by EIA kit assay. The levels of
PGE2 release were measured at 6 h induced by ET-1
(10 nM). ET-1-induced PGE2 release was significantly
blocked by pretreatment with genistein (Gen, 1 μM),
PP1 (10 nM), AG1478 (AG, 10 μM), LY294002 (LY, 300
nM), SH-5 (10 μM), U0126 (U0, 1 μM), SB202190 (SB,
300 nM), or SP600125 (SP, 300 nM) (Figure 7A), sug-
gesting that upregulation of COX-2 is mediated through
c-Src-dependent transactivation of EGFR/PI3K/Akt/
MAPKs pathway associated with PGE2 released by ET-1
in bEnd.3 cells.
Discussion
ET-1 is elevated in the regions of vascular injuries and
inflammation [9,19,44]. Circumstantial evidence has fur-
ther demonstrated that overexpression of ET-1 on endo-
thelial cells has deleterious effects on ischemic brain
[7,10,11]. Additionally, ET-1 has been shown to upregu-
late the expression of COX-2 through MAPKs in various
cell types [25,26,45]. The upregulation of COX-2 has
been shown in several inflammatory diseases and dis-
plays a wide range of biological activities in different tis-
sues, blood vessels in particular, including development,
proliferation, cancers, and inflammation [1,2]. Several
studies have also demonstrated that high levels of PGs,
(See figure on previous page.)
Figure 5 ET-1 stimulates c-Src-dependent transactivation of EGFR/PI3K/Akt leading to MAPKs and c-Jun phosphorylation. (A) For c-Src
phosphorylation, cells were incubated with 10 nM ET-1 for the indicated time intervals in the absence or presence of BQ788 (1 μM), GPAnt2 (1
μM), GPAnt2A (1 μM), AG1478 (1 μM), or LY294002 (300 nM). (B) For EGFR phosphorylation, cells were incubated with 10 nM ET-1 for the
indicated time intervals in the absence or presence of BQ788, GPAnt2, GPAnt2A, or PP1 (100 nM). (C) For Akt phosphorylation, cells were
incubated with 10 nM ET-1 for the indicated time intervals in the absence or presence of BQ788, GPAnt2, GPAnt2A, PP1, AG1478, or LY294002.
(D) For MAPKs phosphorylation, cells were incubated with 10 nM ET-1 for the indicated time intervals in the absence or presence of PP1, AG1478,
or LY294002. For COX-2 expression, cells were incubated with ET-1 (10 nM) for 6 h in the absence or presence of U0126 (1 μM), SB202190 (300
nM), or SP600125 (300 nM). (E) For c-Jun phosphorylation, cells were incubated with 10 nM ET-1 for the indicated time intervals in the absence or
presence of BQ788, GPAnt2, GPAnt2A, PP1, AG1478, LY294002, U0126 (1 μM), SB202190 (300 nM), or SP600125 (300 nM). The cell lysates were
collected and analyzed by Western blotting using an anti-phospho-c-Src, anti-phospho-EGFR, anti-phospho-Akt, anti-phospho-ERK1/2, anti-
phospho-p38 MAPK, anti-phospho-JNK1/2, anti-phospho-c-Jun, or anti-GAPDH (as an internal control) antibody. The figure represents one of
three similar experiments (n= 3).
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synthesized by inducible COX-2, are involved in inflam-
matory responses. However, the mechanisms of ET-1-
induced COX-2 expression in brain endothelial cells
remain unclear. Herein we used cultured models of
mouse brain endothelial cell line (bEnd.3) and applied
Western blot analysis, selective pharmacological inhibi-
tors, transfection with shRNA or siRNAs, ChIP-PCR,
and promoter reporter assay to investigate the signaling
pathways underlying ET-1-induced COX-2 expression
and PGE2 release. Our results demonstrated that in
bEnd.3 cells activation of ETB receptor-mediated c-Src-
dependent transactivation of EGFR, PI3K/Akt, MAPKs
(ERK, p38 MAPK, and JNK), and the AP-1 signaling cas-
cade is essential for ET-1-induced COX-2 gene expres-
sion and PGE2 release.
Several studies have found that an agonist of GPCR
coupling to different G proteins transactivates RTKs
such as EGFR in diverse cell types and sequential linking
to activation of downstream signals such as MAPKs
[19,21,22]. We have demonstrated a significant expres-
sion of ETB receptor in bEnd.3 cells by RT-PCR. Hence,
in this study, the involvement of ETB receptors in these
Figure 6 ET-1-stimulated COX-2 promoter activity is mediated through AP-1-dependent pathway. (A) Time dependence of ET-1-enhanced
AP-1 transcription activity; cells were transfected with an AP-1-luciferase reporter gene and then exposed to ET-1 for the indicated time intervals.
(B) After transfection with AP-1-luciferase reporter gene, the cells were pretreated with PP1 PP1 (100 nM), AG1478 (AG, 1 μM), LY294002 (LY, 300
nM), SH-5 (10 nM), U0126 (U0, 1 μM), SB202190 (SB, 300 nM), SP600125 (SP, 300 nM), or (A) TSIIA (100 nM) for 1 h and then incubated with ET-1
(10 nM) for 90 min. (C) Cells were pretreated without or with TSIIA, U0126 (U0), SB202190 (SB), SP600125 (SP), or BQ788 (BQ) for 1 h and then
incubated with ET-1 (10 nM) for the indicated time intervals (upper panel) or 90 min (lower panel). The c-Jun/AP-1 binding activity was analyzed
by chromatin-IP (ChIP)-PCR assay. (D) For COX-2 promoter activity, cells were pretreated with PP1, AG1478 (AG), LY294002 (LY), SH-5, U0126 (U0),
SB202190 (SB), or SP600125 (SP), or TSIIA for 1 h and then incubated with ET-1 (10 nM) for 6 h. (E) Schematic representation of a 5′-promoter
regions of the mouse different COX-2 promoter constructs, either wild-type (WT) or mutated by single-point mutation of the AP-1 binding site
(mu-AP-1) cloned to the pGL-luciferase reporter gene; the translational start site (+1) of the luciferase reporter gene is indicated by an arrow. Cells
were transfected with WT COX-2 promoter reporter gene (WT) or AP-1 mutated COX-2 promoter reporter gene (mu-AP-1) and then incubated
with or without ET-1 (10 nM) for 6 h. The promoter reporter activity was determined. Data are expressed as mean± SEM of at least three
individual experiments (n= 3). *P< 0.05, #P< 0.01 as compared with ET-1 alone.
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responses was confirmed because pretreatment with
BQ-788 (an ETB receptor antagonist) reduced the ET-1-
stimulated phosphorylation of c-Src, EGFR, Akt, MAPKs
(i.e., ERK, p38 MAPK, JNK), and c-Jun/AP-1 (Figure 5),
but not by an ETA receptor antagonist BQ-123 (data not
shown), suggesting that the ETB receptor predominantly
mediates ET-1 stimulation in these responses in bEnd.3
cells. Next, several subtypes of G proteins are potentially
implicated in ET-1-induced COX-2 expression. We used
GPA2 (a Gi/o protein antagonist) and GPA2A (a Gq pro-
tein antagonist) to interrupt G protein signaling and the
consequent phosphorylation of these signaling molecules
(Figure 5), indicating that ET-1-stimulated c-Src-
dependent transactivation of EGFR is mediated by a
GPCR (i.e., ETB) coupling to either Gi or Gq protein in
bEnd.3 cells, consistent with previous studies from
esophageal smooth muscle cells [45] and rat brain astro-
cytes [20]. In contrast, a report shows that ET-1 induced
COX-2 expression via ETA receptors in peripheral lung
microvascular smooth muscle cells [25]. However, in re-
spiratory and cardiovascular systems, both ET receptor
subtypes, ETA especially, are involved in progression of
airway [46] and cardiovascular diseases [44]. These dif-
ferences may be due to cell-type-specific or different ex-
perimental conditions.
It has been reported that transactivation of RTK,
EGFR especially, occurs in response to activation of
many GPCRs such as endothelin-1 [27,32,39]. Several
lines of evidence have also shown that the βγ complex of
Gi protein activates non-RTKs, such as the c-Src family,
which might transactivate RTKs and modulate various
cellular functions [47,48]. Moreover, the involvement of
c-Src in the transactivation of EGFR by GPCRs has been
reported in various cell types [47,49]. Although transac-
tivation of EGFR by GPCR agonists has been well stud-
ied, the signaling mechanism by which ET-1-stimulated
transactivation of RTK such as EGFR in brain micro-
vascular endothelial cells has not been completely
understood. Thus, in this study, we investigated whether
protein tyrosine kinase pathways, such as c-Src-
dependent transactivation of EGFR, are involved in
ET-1-induced COX-2 expression. First, our data demon-
strated that ET-1-induced COX-2 expression is mediated
through protein tyrosine kinases including c-Src and
EGFR by pharmacological inhibitors and transfection
with a c-Src or EGFR shRNA, which all significantly
inhibited induction of COX-2 gene expression by ET-1
(Figures 1 and 2). Next, we found that ET-1 can stimulate
phosphorylation of c-Src and EGFR via Gi and Gq
protein-coupled ETB receptors (Figure 5A and B), and
following the PP1 significantly inhibited c-Src and EGFR
phosphorylation (Figures 1E and 5B) and subsequent
upregulation of COX-2 (Figure 1C and D) and PGE2 re-
lease (Figure 7A). These results demonstrated that c-Src-
dependent EGFR transactivation plays a critical role in
ET-1-induced COX-2 expression and PGE2 release, con-
sistent with previous reports showing the involvement of
EGFR transactivation in ET-1-induced cell proliferation
in ovarian cancer cells [29] and thrombin- or ET-1-
induced COX-2 expression in VSMCs [4,30,44].
Abnormal MAPK regulation might be implicated in
several models of CNS injury and inflammation [50].
Several lines of evidence demonstrate that MAPKs could
be activated by GPCR agonists by different signal path-
ways [23]. MAPKs activation by ET-1 has been shown to
modulate various cellular responses in various cell types
Figure 7 ET-1-induced PGE2 release is mediated through a c-
Src-dependent transactivation of EGFR/PI3K/Akt cascade. (A)
Cells were incubated with 10 nM ET-1 for 6 h in the absence or
presence of genistein (Gen, 10 nM), PP1 (100 nM), AG1478 (AG, 1
μM), LY294002 (LY, 00 nM), SH-5 (100 nM), U0126 (U0, 1 μM),
SB202190 (SB, 300 nM), or SP600125 (SP, 300 nM), and the
conditioned media were collected to assay the PGE2 level by EIA kit.
Data are expressed as mean± SEM of three individual experiments
(n= 3). #P< 0.01, as compared with cells stimulated by ET-1 alone.
(B) Schematic representation of signaling pathways involved in ET-1-
induced COX-2 expression in bEnd.3 cells. Binding of ET-1 to Gi and
Gq protein-coupled ETB receptors results in c-Src-dependent
transactivation of EGFR/PI3K/Akt linking to MAPKs (e.g., ERK, p38
MAPK, and JNK) and c-Jun/AP-1. The COX-2 transcription is
dependently regulated by MAPK-dependent AP-1 pathways. These
signaling pathways contribute to sustained activation of AP-1
required for COX-2 expression and PGE2 release in bEnd.3 cells.
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[20,24]. Thus, activation of MAPKs may be implicated
in the expression of inflammatory genes in several mod-
els of vascular injury and inflammation [4,51]. Addition-
ally, an agonist of GPCR has been found to transactivate
EGFRs in diverse cell types and shows sequential linking
to MAPK activation, ERK1/2 especially [19,21,22]. Our
data showed that ET-1 stimulated c-Src-dependent
transactivation of the EGFR and PI3K/Akt cascade
(Figure 5A-C), and pretreatment with PP1, AG1478, or
LY294002 attenuated phosphorylation of MAPKs, in-
cluding ERK1/2, p38 MAPK, and JNK1/2 (Figure 5D),
suggesting that ET-1-stimulated activation of MAPKs is
mediated through c-Src-dependent transactivation of the
EGFR and PI3K/Akt cascade. Moreover, ET-1-induced
COX-2 expression was mediated through MAPKs
(Figure 5D, lower panel). Although most studies indicate
that activation of EGFR may lead to ERK1/2 activation
via a Grb2/Sos/Ras/Raf cascade, increasing evidence
demonstrates that transactivation of the EGFR/PI3K/Akt
cascade also plays a critical role in the activation of
ERK1/2. Our results are consistent with previous reports
indicating that BK mediates cell proliferation or throm-
bin induces COX-2 expression via transactivation of the
EGFR and ERK1/2 cascade in VSMCs [4,31], and throm-
bin stimulates cell migration in SMCs [52]. In contrast,
many studies suggest that thrombin-induced mitogenic
action in astrocytes or VSMCs occurs independently of
EGFR transactivation [53,54]. Regarding the MAPKs,
our results are the first to show that p38 MAPK and
JNK1/2 play a critical role in the induction of COX-2 by
ET-1 in brain microvascular endothelial cells.
It has been well established that inflammatory
responses following exposure to extracellular stimuli are
highly dependent on activation of AP-1 transcription
factor, which plays an important role in the regulation of
several gene expressions [41]. The 5′-flanking region of
the COX-2 promoter has been shown to contain several
binding sequences for various transcription factors in-
cluding AP-1 [33,35]. Therefore, the regulation of COX-
2 transcription may be mediated by aberrant activation
of several distinct transcription factors dependent on
agonists [26,55]. These studies suggest that AP-1 plays a
critical role in the regulation of COX-2 expression in the
development of inflammatory responses. Our data
showed that ET-1-induced COX-2 gene expression and
PGE2 release were significantly abolished by an AP-1 in-
hibitor tanshinone IIA (TSIIA) [43] (Figure 4A, B, and
E) or c-Jun (a AP-1 subunit) siRNA (Figure 4D and E),
suggesting that c-Jun/AP-1 is involved in ET-1-induced
COX-2 expression in bEnd.3 cells. Moreover, ET-1-
stimulated c-Jun phosphorylation (Figure 4C) and AP-1-
Luc transcriptional activity (Figure 6A) were significantly
inhibited by TSIIA and three MAPK inhibitors U0126
(MEK1/2), SB202190 (p38 MAPK), or SP600125 (JNK1/
2) (Figures 4C, 5E, 6A, and 6B). Here, we found the in-
hibitory effect of TSIIA on ET-1-stimulated c-Jun phos-
phorylation in bEnd.3 cells, which is consistent with our
recent study in brain astrocytes [56]. Our data further
showed that these ET-1-stimulated responses were sig-
nificantly blocked by PP1, AG1478, and LY294002 in
these cells (Figures 5E, 6B, and 6D). These findings sug-
gested that ET-1-induced COX-2 expression and PGE2
release are mediated through an AP-1-dependent mech-
anism via c-Src-dependent transactivation of EGFR,
PI3K/Akt, and MAPK cascades. These findings are con-
sistent with recent studies indicating that COX-2 expres-
sion induced by phorbol ester (TPA) was mediated by
JNK1/2 and AP-1 activation in human breast epithelial
cell line (MCF-10A) [57] and COX-2 expression induced
by EV-71 via p42/p44 MAPK linking to AP-1 activation
in rat brain astrocytes [58]. The involvement of AP-1 in
ET-1-induced COX-2 expression is also consistent with
previous a report indicating that ET-1-stimulated activa-
tion of AP-1 regulates expression of other target genes
involved in various CNS inflammatory processes [20].
Conclusions
In this study, we demonstrated that the ET-1/ET recep-
tor system exerts its inducing effects on COX-2 gene ex-
pression and PGE2 release in mouse cultured brain
endothelial (bEnd.3) cells. The Gi and Gq protein-
coupled ETB receptor, c-Src-dependent transactivation
of EGFR, PI3K/Akt, ERK1/2, p38 MAPK, JNK1/2, and
c-Jun/AP-1 cascades cooperatively mediated these
effects of ET-1. Based on the observations from the lit-
erature and our findings, Figure 7B depicts a model for
the signaling mechanisms implicated in ET-1-induced
COX-2 gene expression in mouse-cultured bEnd.3 cells.
These findings concerning ET-1-induced COX-2 expres-
sion and PGE2 generation imply that ET-1 might play a
critical role in brain injury, vascular inflammation, and
CNS disorders, mediated by c-Src-dependent transacti-
vation of EGFR linking to MAPKs/AP-1 pathways in
brain microvascular endothelial cells. Pharmacological
approaches suggest that targeting COX-2 and its up-
stream signaling components may provide useful thera-
peutic strategies for brain injury and inflammatory
diseases.
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